KPTI · XBRL financial data

Karyopharm Therapeutics financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (KPTI's year ends in late December)

In millions of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25†Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25†Sep 30, 2025	Q4 FY25†Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Revenue from contracts with customers	36	34*	33	43	39	31*	30	38	44	34*	35	33
Research and development	36	39*	35	38	36	33*	35	33	31	28*	34	29
Selling, general and administrative	31	31*	30	31	28	27*	27	28	27	23*	27	26
Total operating expenses	67	72*	67	71	65	62*	63	62	59	52*	62	56
Operating income (loss)	(31)	(38)*	(34)	(28)	(26)	(31)*	(33)	(24)	(15)	(18)*	(27)	(23)
Interest income	3	3*	2	2	2	1*	1	1	1	1*	1	1
Interest expense	6	6*	6	9	11	11*	11	11	11	13*	13	13
Other income (expense)	0	(0)*	0	14	4	10*	20	(2)	(7)	(10)*	16	(32)
Income tax expense (benefit)	0	0*	0	0	0	(0)*	0	0	0	(0)*	0	0
Net income (loss)	(35)	(42)*	(37)	24	(32)	(31)*	(23)	(37)	(33)	(102)*	(22)	(67)
Earnings per share, basic USD per share	(0.30)	(0.36)*	(0.32)	0.15	(0.26)	—	(2.77)	(4.32)	(3.82)	—	(1.02)	(2.32)
Earnings per share, diluted USD per share	(0.30)	(0.36)*	(0.32)	(0.20)	(0.26)	—	(2.77)	(4.32)	(3.82)	—	(1.24)	(2.32)
Weighted average shares, basic millions of shares	114	115*	115	121	0	—	0	0	0	—	0	0
Weighted average shares, diluted millions of shares	114	115*	115	154	0	—	0	0	0	—	0	0

† Share count changed about 1/15 in the period ending 2025-03-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
† Share count changed about 1966x in the period ending 2025-09-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
† Share count changed about 1/930 in the period ending 2025-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal quarters (KPTI's year ends in late December)

In millions of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25†Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25†Sep 30, 2025	Q4 FY25†Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Cash and cash equivalents	44	52	31	85	73	62	39	39	38	61	91	55
Marketable securities	165	139	118	67	61	46	31	13	8	3	0	10
Inventory	3	3	3	3	5	5	5	5	4	4	4	4
Prepaid and other current assets	13	12	15	15	15	12	10	8	8	9	9	7
Total current assets	263	234	198	209	185	156	120	98	90	103	126	106
Property and equipment, net	1	1	1	1	0	0	0	0	0	0	0	0
Right-of-use asset	5	4	4	3	3	6	5	5	5	5	4	4
Total assets	270	240	204	214	189	164	128	105	96	108	131	111
Accounts payable	1	3	5	3	6	5	6	3	5	4	4	8
Accrued liabilities	56	61	55	50	50	61	57	63	66	64	76	79
Total current liabilities	62	69	65	58	61	92	90	99	87	92	117	134
Lease liability, non-current	4	3	2	1	0	7	6	6	6	6	5	5
Total liabilities	370	377	373	346	349	350	334	344	365	401	397	441
Accumulated deficit	(1,445)	(1,487)	(1,524)	(1,501)	(1,533)	(1,563)	(1,587)	(1,624)	(1,657)	(1,759)	(1,782)	(1,849)
Total stockholders' equity	(100)	(136)	(169)	(132)	(160)	(186)	(206)	(239)	(269)	(293)	(266)	(330)
Total liabilities and equity	270	240	204	214	189	164	128	105	96	108	131	111
Common shares outstanding (cover page) millions of shares	115	115	118	125	125	126	9	9	17,051	18	23	23

† Share count changed about 1/15 in the period ending 2025-03-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
† Share count changed about 1966x in the period ending 2025-09-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
† Share count changed about 1/930 in the period ending 2025-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal quarters (KPTI's year ends in late December)

In millions of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25†Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25†Sep 30, 2025	Q4 FY25†Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Net income (loss)	(35)	(42)*	(37)	24	(32)	(31)*	(23)	(37)	(33)	(102)*	(22)	(67)
Stock-based compensation	5*	5*	5	5*	4*	4*	4	4*	3*	4*	3	2*
Net cash from operating activities	(30)*	(19)*	(44)	(38)*	(19)*	(26)*	(39)	(19)*	(6)*	(12)*	(23)	(25)*
Purchases of property and equipment	0*	0*	0	0*	0*	(0)*	0	0*	0*	0*	—	—
Net cash from investing activities	(8)*	27*	22	51*	7*	15*	15	18*	5*	5*	3	(10)*
Proceeds from issuing common stock	—	—	—	—	—	—	0	0*	—	—	20	0*
Net cash from financing activities	0*	0*	—	—	0*	1*	0	0*	0*	30*	50	(1)*
Net change in cash	(37)*	9*	(22)	54*	(12)*	(10)*	(24)	(0)*	(1)*	23*	30	(36)*

† Share count changed about 1/15 in the period ending 2025-03-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
† Share count changed about 1966x in the period ending 2025-09-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
† Share count changed about 1/930 in the period ending 2025-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Karyopharm Therapeutics	55	33	(25)*	22.7M	2.6 quarters	Q2 FY26 10-QJun 30, 2026
Abvc Biopharma	0	not reported	(0.2)*	26.7M	0.4 quarters	Q2 FY26 10-QJun 30, 2026
BriaCell Therapeutics	9.9	not reported	(6)*	8.7M	3.4 quarters	Q4 FY26 10-KJul 31, 2026
Annovis Bio	19	0*	(22)*	42.6M	0.9 quarters	Q2 FY26 10-QJun 30, 2026
Atara Biotherapeutics	3.2	0.6	(3.3)*	10.0M	3.0 quarters	Q2 FY26 10-QJun 30, 2026
Grace Therapeutics	14	not reported	(3.2)	21.0M	4.3 quarters	Q1 FY27 10-QJun 30, 2026
CervoMed	22	0	(6.9)*	15.1M	3.6 quarters	Q2 FY26 10-QJun 30, 2026
Kezar Life Sciences	66	not reported	(7.4)	7.4M	8.9 quarters	Q1 FY26 10-QMar 31, 2026
Actuate Therapeutics	4.4	not reported	(4.4)*	24.0M	1.0 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.